14 November 2022


Nigel Gordon, capital markets and M&A partner at Fladgate LLP, explores the IPO potential of psychedelics companies 

Only a few years ago it would not have been realistic to propose the IPO of a psychedelics company on any London markets. This is because of a lack of understanding, and therefore minimal acceptance, of psychedelics by investors and because of potential problems under the Proceeds of Crime Act 2002 (POCA).

However, times are changing. First, the FCA has given guidance about floating medicinal cannabis companies and we believe that the guidance can be applied to psychedelics companies. Secondly, there has been a growing awareness recently of how widespread mental illness is and of the potential of psychedelic drugs to treat certain mental illnesses effectively. The success of the Netflix series “How to change your mind” is evidence of psychedelics’ journey towards the mainstream. Finally, an ecosystem of leading academic research and expertise in clinical trials has developed in the UK and elsewhere, led in the UK by Imperial College London and King’s College London.

We consider that the investment community is likely to recognise these points and we therefore consider that there may well be an opportunity for psychedelics companies to carry out an IPO on one of the UK markets. Investment into UK-based psychedelics ventures, typically led by newly-established specialist funds and private family offices, is starting to gather pace, although listings of such businesses have so far taken place only in the US, such as Compass Pathways on NASDAQ, or Canada, such as Small Pharma on the TSX-V.

What are psychedelics?

“Psychedelics” are a class of psychoactive substances i.e. a substance that is capable of producing a psychoactive effect. By stimulating or depressing the person’s central nervous system, a substance affects the person’s mental functioning i.e. it produces temporary changes in perception, mood and cognitive processes. The psychedelic most often referred to is psilocybin, which is the active ingredient in so-called “magic mushrooms”. However, that is by no means the only psychedelic. Psilocybin can also be synthesised, that is produced in a laboratory.

How widespread is mental illness?

Mental health issues affect many people. Recent estimates state that in the UK one in six adults experienced a “common mental disorder” such as depression or anxiety in the past week and one in six children aged between six and 16 experienced a “common mental disorder” in 2021. In 2020, the leading cause of death for people in the UK aged five to 34 was “intentional self-harm”. In 2021 the World Health Organisation estimated that one in four people in the world will be affected by mental or neurological disorders at some point in their lives. Levels of depression and anxiety, are reported to be at a global all-time high, which is not surprising following the Covid-19 pandemic and worldwide lockdowns.

Clearly there is a great need for effective treatments for mental illness. Many instances of depression do not respond to traditional therapies or drug treatments.  If psychedelics can add to the treatments that doctors can use, then this would have the potential to improve people’s lives significantly. Psychedelics companies would then have a role to play in researching, developing and eventually supplying such treatments, and that role would benefit both the world at large and psychedelics companies.

Why are psychedelics potentially useful?

Research is being carried out worldwide into the potential use of psilocybin in treating depression, PTSD, anorexia, tobacco addiction and alcohol dependency.

Recently there has been increasing focus on, and public acceptance, on the use of psilocybin. For example, in early November 2022 it was announced that a peer-reviewed, mid-stage trial found one 25mg dose of psilocybin, alongside psychotherapeutic support, “significantly” reduced symptoms of depression in patients who did not respond to other medication. It has also been suggested that psilocybin has fewer unwelcome side effects than other medication. It is thought that psilocybin works on receptors in the brain associated with “re-ordering” the way we think about things. There have been calls in Parliament to legalise psilocybin in response to the potential for treatment of mental health conditions. Psychedelics are therefore expected to be an area of interest for investors in the near future.

What impediments to investment does current drugs legislation present?

The main UK controlled drugs legislation are the Misuse of Drugs Act 1971 (MDA) and the Misuse of Drugs Regulations 2001 (MDR), each as amended. Schedule 2 contains of the MDA the definition of a controlled drug and sets out a three-tier system: classes A, B and C. Class A drugs are considered the most harmful and have the highest level of control. Psilocin is a psychedelic drug listed as a Class A drug. Psilocin and its derivative psilocybin are therefore controlled drugs.

The MDA describes a number of criminal offences relating to controlled drugs including prohibitions on: importation and exportation; production and supply; and possession. However, the MDA sets out some exceptions and defences, in particular, where the handling and use of the controlled substance in the UK has been licensed by the Home Office pursuant to its powers under the MDR. Investors have therefore rightly been wary of companies that might be considered to be committing a criminal offence, particularly as any investment might generate “criminal proceeds” in the hands of an investor under POCA.

The medicinal cannabis precedent

On 18 September 2020 the FCA issued guidance relating to the listing of cannabis-related businesses setting out its approach to cannabis-related companies interested in listing in the UK. The FCA guidance categorises UK and overseas businesses separately, as discussed below.

In relation to UK cannabis-related operations, the position is straightforward: the FCA guidance states that “UK-based medicinal cannabis companies can be admitted to the Official List, if the company has the appropriate Home Office licences for their activities where they are required.

As regards overseas companies, the FCA guidance states that “For medicinal cannabis and cannabis oil companies with overseas activities, the company will need to satisfy us that their activities would be legal if carried out in the UK. We will also need to understand the legal basis of the company’s overseas activities, for example the nature of the local licensing and the licences the company holds.”

In July 2021 the FCA issued a draft technical note (TN 104.1) setting out in further detail the FCA’s approach to the listing of companies carrying on cannabis-related activities. TN 104.1 remains in draft, but we consider that it provides a useful indication of how the FCA would view the listing of a company carrying on cannabis-related activities. One may also reasonably assume that TN 104.1 can be taken to show how the listing or admission of a company carrying on cannabis-related activities on AIM or AQSE should be approached.

The FCA guidance and TN 104.1 make it clear that provided due diligence is carried out over and above that which would normally be expected on a listing then the FCA will consider listing a company developing, producing or selling cannabis-based medicinal products, licensed cannabis-based medicines or consumer products containing CBD.

In summary, if the FCA is satisfied that if a company with the entirety of its operations, including supply chain, in the UK holds the appropriate Home Office licences for their activities, then the FCA will permit that company to list.

By contrast, the securities of a company with cannabis-related activities legally operated overseas may be listed, provided the FCA is satisfied its business does not give rise to any money laundering offence under POCA. A company with cannabis-related activities legally operated overseas will need to satisfy the FCA that those activities are for a purpose that is also lawful in the UK.

The FCA will also need to understand the legal basis of the company’s overseas activities, for example the nature of the local licensing and the licences the company holds. To satisfy the FCA on these points, after consideration of the company’s operations and the relevant jurisdictions, the FCA will request appropriate legal opinion(s) on the overseas company’s cannabis activities. Any legal opinion(s) should at least address the following points:

the activities of the company; confirmation of the legality of each of the activities covered by the opinion; confirmation that such an activity or activities are for purposes which are lawful in the UK; where relevant, information about the jurisdiction’s licensing system; and details of the track record of the company carrying out the activities in question.

How does the medicinal cannabis precedent apply to psilocybin?

We believe that the regulatory framework and approach for the listing of a psilocybin company would be the same as for a medicinal cannabis company. Both cannabis and psilocybin are controlled drugs listed in Schedule 1 to the MDR and therefore conceptually should be treated in the same way.

In 2018 there was a rescheduling of cannabis-based products for medicinal use in humans (or CBPMs) prior to market authorisation as a medicine, to allow those products to become available for prescription, under the supervision of specially qualified medical professionals, without the need for a Home Office licence. This was on the basis that there was conclusive evidence of the therapeutic benefit of CBPMs for certain medicinal conditions, and reasonable evidence of therapeutic benefit in several other medical conditions. The rescheduling was intended to act as a spur to further research and testing of such products, recognising that it would be significantly easier for scientists to research CBPMs under Schedule 2 controls. It is surely no coincidence that there have been a number of listings of medicinal cannabis-focussed companies on the UK markets since 2018.

A similar rescheduling of psilocybin is not imminent, but there are well-regarded lobby groups which propose moving psilocybin into the less restrictive Schedule 2 category (as for CBPMs) for research purposes. There is a scientific consensus that it exhibits negligible toxicity or addictive properties. Clearly the “direction of travel” in the thinking about psilocybin is towards a conclusion that it may form the basis of the development of much-needed novel treatments for mental health conditions.

We therefore consider that once the current volatility in the markets lessens there could be an opportunity for psychedelics companies to conduct an IPO in the UK.

Nigel Gordon is a capital markets and M&A Partner at Fladgate LLP, with a particular focus on the healthcare and natural resources sectors.


Related News

February 2024 News

Diversity: The way we were

What is diversity? Despite a multiplicity of available definitions, there is no straightforward answer to this apparently simple question. Indeed, the 5.6 billion results provided by a quick Google search of the word shows that diversity ranks midway between comparable searches for the word God (6.6 billion) and religion (4.6 billion).

February 2024 News

Diversity: The way we live now

No one can doubt that law firms are significantly more diverse than they were a generation ago.

February 2024 News

Diversity: The shape of things to come

Predicting the future is always dangerous. But one prediction can be made with a degree of certainty: the more diverse that law firms become, the less their commitment to diversity will need to be analysed and discussed.

February 2024 News

Diversity and inclusion in the legal profession: A personal perspective

Drawing on her own experience, Tameka Davis, Partner and Chair of Conyers’ Global Diversity and Inclusion Committee, outlines her thoughts on D&I priorities